Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:94-9.

Trastuzumab: updates and future issues.

Toi M, Horiguchi K, Bando H, Saji S, Chow LW.

Source

Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Honkomagome 3-18-22, Bunkyo-ku, Tokyo, 113-8677, Japan. maktoi77@wa2.so-net.ne.jp

Abstract

Trastuzumab has had an enormous impact on the clinical management of breast cancer: the survival of Her-2-positive metastatic breast cancer patients has improved significantly and tumor Her-2 status has been built into the decision-making tree for primary breast cancer patients. Several pioneering studies have shown that trastuzumab-combined chemotherapy elicits high levels of pathological complete response in the neoadjuvant setting. Currently, therefore, a more precise understanding of the mechanisms of therapeutic response is needed so that trastuzumab-based therapies can be optimized more individually. It might also be important to investigate, with greater depth, the interaction between the Her-axis and the hormone-axis. This short review describes and discusses these topics.

PMID:: 16273357; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

Review Overview of resistance to systemic therapy in patients with breast cancer. [Adv Exp Med Biol. 2007]
Review Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Adv Exp Med Biol. 2007; 608:1-22.
Review HER-2-targeted therapy: lessons learned and future directions. [Clin Cancer Res. 2003]
Review HER-2-targeted therapy: lessons learned and future directions.
Nahta R, Esteva FJ. Clin Cancer Res. 2003 Nov 1; 9(14):5078-84.
Review Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. [BMC Cancer. 2007]
Review Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. BMC Cancer. 2007 Aug 8; 7:153. Epub 2007 Aug 8.
HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. [Anticancer Res. 2006]
HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T. Anticancer Res. 2006 Jan-Feb; 26(1B):647-53.
Review The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. [Breast Cancer. 2009]
Review The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y, Suzuki Y, Saito Y, Umemura S. Breast Cancer. 2009; 16(4):295-300. Epub 2009 Jul 17.

See reviews... See all...

Cited by 1 PubMed Central article

Immunotherapy for advanced prostate cancer. [Rev Urol. 2007]
Immunotherapy for advanced prostate cancer.
Vieweg J. Rev Urol. 2007; 9 Suppl 1:S29-38.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Trastuzumab: updates and future issues.
Trastuzumab: updates and future issues.
Cancer Chemother Pharmacol. 2005 Nov ;56 Suppl 1:94-9.

PubMed
Thimerosal induces neuronal cell apoptosis by causing cytochrome c and apoptosis...
Thimerosal induces neuronal cell apoptosis by causing cytochrome c and apoptosis-inducing factor release from mitochondria.
Int J Mol Med. 2005 Dec ;16(6):971-7.

PubMed
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Nature. 2006 Jan 19 ;439(7074):353-7. Epub 2005 Nov 6 .

PubMed
Mapping of conserved RNA secondary structures predicts thousands of functional n...
Mapping of conserved RNA secondary structures predicts thousands of functional noncoding RNAs in the human genome.
Nat Biotechnol. 2005 Nov ;23(11):1383-90.

PubMed
Pulsatile tinnitus: a review of the literature and an unusual case of iatrogenic...
Pulsatile tinnitus: a review of the literature and an unusual case of iatrogenic pneumocephalus causing pulsatile tinnitus.
Otol Neurotol. 2005 Nov ;26(6):1149-51.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Trastuzumab: updates and future issues.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information